Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Wide testimony as committee reconsiders how to regulate high‑potency kratom products
Summary
Senate Bill 557 drew hours of testimony from clinicians, vendors, recovery providers and industry groups about concentrated and synthetic 'cratom' products; sponsors urged restoration of a Senate committee version with product standards while opponents warned bans could harm patients and push users to illicit markets.
The Criminal Justice and Public Safety Committee devoted a major portion of the day to a contentious public hearing on SB557, a bill offered to regulate concentrated and synthetic "cratom" products and to set an under‑21 sales limit.
Senator Deborah Uler, the prime sponsor, urged the panel to restore the Senate committee amendment that would have required potency limits, child‑resistant packaging, labeling of alkaloid content and licensing/enforcement by the Department of Health and Human Services. She said a subsequent floor amendment gutted much of that regulatory framework and left concentrated products largely unaddressed.
Medical witnesses—emergency clinicians and addiction…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
